- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
This study is testing a new medicine, Vixarelimab, for two serious lung conditions: Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease. It aims to see if the medicine can improve lung function and safety compared to a dummy treatment.
For: Idiopathic Pulmonary Fibrosis · Systemic Sclerosis-Associated Interstitial Lung DiseaseGermany · Hungary · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter Induction Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
This study is testing a new drug, called Vixarelimab, for adults with moderate to severe ulcerative colitis. It aims to see how well it works to reduce symptoms and improve the gut, as well as checking its safety and how the body handles it.
For: Ulcerative Colitis (UC)Belgium · Germany · France